INO-4885 [5,10,15,20-tetra[N-(benzyl-4'-carboxylate)-2-pyridinium]-21H,23H-porphine iron(III) chloride], a peroxynitrite decomposition catalyst, protects the heart against reperfusion injury in mice.

Oxidative/nitrative stress caused by peroxynitrite, the reaction product of superoxide (O2(.-)) and nitric oxide (NO), is the primary cause of myocardial ischemia/reperfusion injury. The present study determined whether INO-4885 [5,10,15,20-tetra[N-(benzyl-4'-carboxylate)-2-pyridinium]-21H,23H-porphine iron(III) chloride], a new peroxynitrite decomposition catalyst, may provide cellular protection and protect heart from myocardial ischemia/reperfusion injury. Adult male mice were subjected to 30 min of ischemia and 3 or 24 h of reperfusion. Mice were randomized to receive vehicle, INO-4885 without catalytic moiety, or INO-4885 (3-300 microg/kg i.p.) 10 min before reperfusion. Infarct size, apoptosis, nitrotyrosine content, NO/O2(.-) production, and inducible nitric-oxide synthase (iNOS)/NADPH oxidase expression were determined. INO-4885 treatment reduced ischemia/reperfusion-induced protein nitration and caspase 3 activation in a dose-dependent fashion in the range of 3 to 100 microg/kg. However, doses exceeding 100 microg/kg produced nonspecific effects and attenuated its protective ability. At the optimal dose (30 microg/kg), INO-4885 significantly reduced infarct size (p < 0.01), decreased apoptosis (p < 0.01), and reduced tissue nitrotyrosine content (p < 0.01). As expected, INO-4885 had no effect on ischemia/reperfusion-induced iNOS expression and NO overproduction. To our surprise, this compound significantly reduced superoxide production and partially blocked NADPH oxidase overexpression in the ischemic/reperfused cardiac tissue. Additional experiments demonstrated that INO-4885 provided better cardioprotection than N-(3-(aminomethyl)benzyl)acetamidine (1400W, a selective iNOS inhibitor), apocynin (an NADPH oxidase inhibitor), or Tiron (a cell-permeable superoxide scavenger). Taken together, our data demonstrated that INO-4885 is a cardioprotective molecule that attenuates myocardial reperfusion injury by facilitating peroxynitrite decomposition and inhibiting NADPH oxidase-derived O2(.-) production.
AuthorsXiang-Ying Jiao, Erhe Gao, Yuexin Yuan, Yajing Wang, Wayne Bond Lau, Walter Koch, Xin-Liang Ma, Ling Tao
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 328 Issue 3 Pg. 777-84 (Mar 2009) ISSN: 1521-0103 [Electronic] United States
PMID19033557 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • (5,10,15,20-tetrakis(N-(benzyl-4'-carboxylate)-2-pyridinium)-21H,23H-porphine)iron(III)
  • Metalloporphyrins
  • Peroxynitrous Acid
  • Nitric Oxide Synthase Type II
  • NADPH Oxidase
  • Caspase 3
  • Animals
  • Apoptosis (drug effects)
  • Caspase 3 (metabolism)
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Heart (drug effects, physiology, physiopathology)
  • Male
  • Metalloporphyrins (therapeutic use)
  • Mice
  • Myocardial Infarction (prevention & control)
  • NADPH Oxidase (drug effects, genetics)
  • Nitric Oxide Synthase Type II (drug effects, genetics)
  • Oxidative Stress (drug effects, physiology)
  • Peroxynitrous Acid (therapeutic use)
  • Reperfusion Injury (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: